29th Pharmacovigilance 2022
10th November 2022, Hotel Kohinoor Continental, Mumbai, India
Our conference provides the foundation for strong strategic planning and practical decision-making in your pharmacovigilance programs. This year’s conference will address the current thinking on predicting and assessing risks such as drug-induced liver injury, and the assessment of expectedness of serious adverse reactions during clinical development. Experts will present approaches and engage in dialogs around more extensive and impactful uses of real world data and generation of RWE for safety assessments. A full-day will be devoted to the development, implementation, and assessment of risk management strategies for drugs approved in multiple regions.
DELEGATE REGISTRATION:
Please contact Email - bookings@virtueinsight.com or Call - +91 44 42108101/ +91 9361957193
- Standard Price - INR 15,000 + GST (18%) per delegate
- Conference Sponsor & Exhibition Stall – Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries
KEY SPEAKERS:
- K BANGARURAJAN, Adviser, CDSCO (New Delhi)
- SAKSHI SHRIVASTAVA DESAI, Associate Director International Pharmacovigilance Strategy Realization, Johnson & Johnson
- MUKESH GORI, Associate Director - ESP Management PV Operations, Novartis
- VAIBHAV KULKARNI, Director - Regulatory Affairs, Abbott Nutrition
- SACHIN MANGALVEDHEKAR, Vice President and Head- Clinical and PV QA, Glenmark
- FATIMA YOUSEF GHETHAN, Quality Culture & Implementation Manager, Executive Administration of Quality & Patient Safety, Makkah Healthcare Cluster (UAE)
- ANUJA JAWALE, Associate Director RA and PV Strategic Sourcing and Vendor Management, Organon
- ANJU AGARWAL, Director Global Patient Safety, Advanz Pharma
- VIPIN SETHI, Global Head – Pharmacovigilance Head – Medical Affairs – ISBU, Cadila
- UJWALA NAIK, Country Safety Head, Johnson & Johnson
- MILIND ANTANI, Leader, Pharma and Healthcare, Nishith Desai Associates
- GEETA SHANBHAG, Vice President - Pharmacovigilance and Medico-regulatory Affairs, Ipca Laboratories
- RISHI JAIN, Director Medical Affairs, Medical Information and Pharmacovigilance, AbbVie
- DILIP PAWAR, Head – Medical Affairs and Pharmacovigilance, Unichem Laboratories
- JAMAL BAIG, Multi Country Safety Head, Sanofi
- VALLABH DESHPANDE, Head of Global PV Operations, Glenmark
- SIVA KUMAR BUDDHA, Global Phv Surveillance Physician Sr Manager, Teva
- VRUNDA PANDYA, Deputy General Manager – Quality Assurance, SPARC
- SADANAND KULKARNI, Head-Medical, Regulatory, Vigilance, Quality, Fresenius Kabi
- RAJENDRA KUMAR KASI, Head - Global Pharmacovigilance, Zydus Group
- VARSHA KHATRY, Head Medical and Scientific Affairs, Quality and Regulatory, Roche
- INDU NAMBIAR, Local Patient Safety Lead, Boehringer Ingelheim
- WASIMUZZAMA KHAN, India QPPV (PvOI) & Sr. SDEA Specialist, Haleon
- VISHWAS SOVANI, Founder Director, Pharmawisdom
- PRASHANT BODHE, Director, CliniSearch
- KAVYA KADAM, Consultant Global Clinical Trials
- TARUN BISWAS, Manager – Quality and Compliance (Pharmacovigilance), Ipca Laboratories
Plus more joining soon
FOCUSES ON:
- Overcoming this pandemic issues - Drug safety strategy for pharmaceutical organisations
- Lessons learnt from the pandemic
- Unique challenges in signal detection for vaccines
- Future of Signal Detection – Analyzing the risk and benefit
- What are the recent trends in Good Pharmacovigilance Practice?
- Adverse event reporting – how devices make better things?
- AI and automation in PV? – Recent improvements
- Ensure the patient safety and quality of products concurrently – What are the ways?
- Role of technology in patient safety and monitoring – Significance
- Digital Adverse event monitoring and Electronic Health Records – Risks and benefits?
- Potential analyzing of safety and risk signals – How technology makes difference?
- How will data analytics make a better way to avoid risks?
- REMS – New challenges and chances
- Addressing pharmacovigilance audit based on risk assessment.
- PV inspections under post pandemic situation
- Benefits and challenges of implementing RWD and RWE
- RWE and RWD solutions for regulatory barriers
- Current and future trends in PV regulations
- Drug regulations changes – How do companies and CRO’s handle?
- Be part of a major networking opportunity
WHO SHOULD ATTEND:
CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:
Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales and Marketing
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the virtual exhibition area. Expand your knowledge of the latest business models and strategies in the high-level conference.